卡托普利联合辛伐他汀治疗早期糖尿病肾病临床观察

The clinical efficacy of captopril combined with simvastatin for treating patients with early diabetic nephropathy

目的观察卡托普利联合辛伐他汀治疗早期糖尿病肾病的临床疗效。方法180例糖尿病肾病患者随机分为三组，每组60例，A组选择卡托普利治疗，B组辛伐他汀治疗，C组卡托普利配合辛伐他汀治疗；比较三组的疗效、治疗前后的肾功能指标及不良反应发生率。结果治疗后，A组显效21例、有效27例、无效12例、总有效率80．0％，B组分别18例、28例、14例、76．7％，C组分别为30例、24例、6例、90．0％，B组与C组总有效率差异无统计学意义（x2=1．27，P〉0．05）；C组总有效率明显高于A组和C组（x2=3．42、4．65，均P〈0．05）。治疗后，三组各项指标均较治疗前降低（t=3．12、3．08、3．17、3．41、3．19、3．20、3．04、3．44、3．48，均P〈0．05），且C组治疗后各项指标明显低于A组及B组（t=4．58、4．69、5．02、4．89、5．11、4．87，均P〈0．05）。结论卡托普利联合辛伐他汀能显著提高早期糖尿病肾病的临床疗效，且不良反应小。

Objective To observe the clinical efficacy of eaptopril combined with simvastatin for treating pa- tients with early diabetic nephropathy. Methods 180 patients with diabetic nephropathy were randomly divided into three groups, and each group had 60 cases, group A was given captopril for treatment, group B was given simvastatin and group C was received eaptopril and simvastatin for treatment. The clinical effieaey lrenal function before and after treatment and incidence of adverse reactions were compared in three groups. Results The clinical efficacy of group C was significantly better than group A and group B （ P 〈 0.05 ） ; after treatment, the value of Ma/Cr, SCR and Bun of three groups were lower than pre-treatment （ t = 3.12,3.08,3.17,3.41,3.19,3.20,3.04,3.44,3.48, all P 〈 0.05 ） ; and the value of Ma/Cr,SCR and Bun after treatment in group C were significantly lower than group A and group B （ t = 4.58,4.69,5.02,4.89,5.11,4.87, all P 〈 0.05 ） ; the incidence of adverse reactions in group C was significant- ly lower than the other two groups. Conclusion Captopril combined with simvastatin could significantly improve the clinical efficacy of the early diabetic nephropathy and had small side effects.